TuHURA Biosciences (NASDAQ:HURA - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Friday.
A number of other research firms have also recently commented on HURA. HC Wainwright reissued a "buy" rating and issued a $12.00 price target on shares of TuHURA Biosciences in a report on Friday, May 16th. Brookline Capital Management raised TuHURA Biosciences to a "strong-buy" rating in a report on Monday, June 23rd. One research analyst has rated the stock with a hold rating, three have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, TuHURA Biosciences presently has a consensus rating of "Buy" and an average target price of $12.67.
Read Our Latest Analysis on TuHURA Biosciences
TuHURA Biosciences Stock Up 3.6%
Shares of HURA stock traded up $0.09 during trading hours on Friday, reaching $2.62. 348,645 shares of the company traded hands, compared to its average volume of 262,411. TuHURA Biosciences has a 12-month low of $1.80 and a 12-month high of $7.93. The firm has a 50-day moving average price of $2.81 and a 200 day moving average price of $3.45.
TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02).
Institutional Trading of TuHURA Biosciences
A number of large investors have recently added to or reduced their stakes in HURA. Accent Capital Management LLC bought a new stake in TuHURA Biosciences in the 4th quarter worth approximately $29,000. TT Capital Management LLC bought a new stake in TuHURA Biosciences in the 4th quarter worth approximately $41,000. Jefferies Financial Group Inc. bought a new stake in TuHURA Biosciences in the 4th quarter worth approximately $54,000. Bank of America Corp DE bought a new stake in TuHURA Biosciences in the 4th quarter worth approximately $59,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in TuHURA Biosciences in the 4th quarter worth approximately $61,000. Institutional investors own 0.62% of the company's stock.
TuHURA Biosciences Company Profile
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
